Male breast carcinoma remains a very rare disease, with approximately one male being affected for every 100 cases of human breast carcinoma. The average annual death rate for male breast carcinoma from [1968] [1969] [1970] [1971] [1972] [1973] [1974] [1975] [1976] [1977] [1978] in England and Wales (Gardner et al., 1983) was 874 men or 3 per million compared to 123,636 women with breast carcinoma or 448 per million.
Very few series have been reported from single Institutions (Holleb et al., 1968; Scheike, 19.75; Langlands et al., 1976 ) and the paucity of cases has led to several series being pooled in reviews of the world literature (Meyskens et al., 1976; Everson & Lippman 1979) .
The Author has previously reported on 200 cases of male breast carcinoma; (Ribeiro, 1977) an additional 101 patients have since been registered at The Christie Hospital & Holt Radium Institute giving a total of 301 cases. It was felt that an analysis of this series would reflect the changes that have taken place in the management of this disease.
Patients
The clinical records of all the patients have been carefully studied and, for the sake of uniformity, the clinical staging used throughout has been that of the UICC International Staging of 1968.
Histological confirmation was available in all the patients except a very few with Stage IV disease. Survival curves show the acturial survival rates. These have been calculated firstly to include all deaths whatever the cause and, secondly, counting deaths from breast carcinoma only. A patient who dies from intercurrent disease at time T after treat- Received 11 June 1984; and in revised form, 8 October 1984. ment, is included as being at risk up to the time T and then omitted from the group at all times greater than T. Significant differences between curves were calculated by the use of the log Rank test (Peto & Peto, 1972) .
Since 1974, the following investigations are carried out whenever possible on all patients registered at The Christie Hospital: Full blood count, biochemical profile, X-rays of the chest, lumbar spine and pelvis and a whole body Technetium 99 bone scan.
More specialised investigations have included estimation of serum oestradiol-17beta, testosterone, luteinizing hormone (LH) and follicle stimulating hormone (FSH) concentrations by standard radioimmunoassay methods. Where tumour tissue was available Oestrogen (REC) and Progesterone (RPC) receptors have been measured by the dextran charcoal method previously described (Barnes et al., 1977) .
Survival curves show acturial survival rates and have been calculated in two ways; first, including all deaths whatever the cause and secondly counting deaths from breast carcinoma only. A patient who dies of intercurrent disease at time T after treatment is included as being at risk up to time T and then omitted from the group at risk at all times greater than T. Significant differences between curves were worked out by using the log Rank test (Peto & Peto, 1972 Because of the skewed distributions in values between the male breast carcinoma patients and controls, the non-parametric Mann-Whitney U test (Siegel, 1966) has been used. The differences were regarded as significant when P < 0.02. The mean values of breast carcinoma males showed no statistically significant differences from controls for oestradiol-17 beta (z=1.59 P=0.11), LH (z=1.81 P=0.07), FSH (z= 1.87 P=0.06) testosterone (z= 1.59 P=0.11).
Oestrogen (REC) and Progesterone (RPC) receptors have been measured in 22 patients with male breast carcinoma primary tumours and 6 secondary skin deposits. The dextran charcoal method previously described by Barnes et al. (1977) was used. A specimen was regarded as having positive cytoplasmic activity if it contained a minimum of 5fmolmg-1 cytosol protein for REC and 15fmolmg-1 cytosol protein for RPC. The protein concentration had to be at least 0.7mgl-1. Thirteen of the 16 primary tumours (81%) showed positive receptor activity; 9/16 primary tumours were positive for both REC and RPC, 3 were positive for REC only and one positive for RPC only. Of the 6 secondary tumours 3 were positive for REC and 3 for RPC. There was no correlation between REC and RPC concentration and the age of the patient. A survey of the world literature (Everson & Lippman, 1979) showed that REC was present in 84% of tumour samples from MBC patients and RPC in 73%; a significant negative correlation was found between REC concentration and age, which was absent in the present series. There is no significant difference in the corrected survival of these age groups (P = 0.14).
The effect of delay in presentation on survival is shown in Figure 2 . Although the patients presenting within the 6-11 month period appear to have a poor survival, overall the trend is significantly in favour of those patients presenting earlier (X2 for trend=5.21 ondfP=0.02) 
Survival
The overall survival of the whole group of 292 patients was 44%, 23% and 14% at 5, 10 and 15 years respectively. When corrected for intercurrent deaths, the equivalent figures are 52%, 38% and 36%. The high rate of death from causes other than male breast carcinoma has been previously noted (Scheike, 1975; Moss, 1964; Norris & Taylor, 1969) and, for the latter reason, the following survival curves have all been corrected (cf. Methods and Statistics). In a previous report (Ribeiro, 1977) can be seen that the corrected survival of these 23 patients now approximates that of the female patients with a 5 year survival of 55% compared to 28% previously. The numbers of patients treated with adjuvant Tamoxifen is as yet very small. Furthermore there are dangers in suggesting improved survival benefit with the use of historical controls, but with a disease as rare as male breast carcinoma, it would be impossible to get enough patients to run a controlled clinical trial even on ain international basis.
Double primary tumours
In the present series, 5% of patients were treated for other primary malignant tumours; these were all subsequent to treatment for male breast carcinoma. Histological material was available in all cases so there was no question of these tumours being metastatic disease. Other authors have noted this phenomenon and reported an incidence varying from 7.5% to 12.5% in their series (Holleb et al., 1968 , Scheike 1975 Langlands et al., 1976) . In all the series there has been a preponderance of carcinoma of the large intestine (45%). Other second primary tumours in the present series include carcinomas of the stomach, bladder, pancreas, skin, testis and lung. One patient had male breast carcinoma followed by chronic lymphatic leukaemia, carcinoma of the large bowel and, basal cell carcinoma of the skin all of which were successfully treated,, the patient dying at the age of 85 years.
Recurrence/metastases
The majority of patients who develop recurrent disease in the operative flaps and/or lymph node drainage areas do so within 3 years of surgery.
There is no significant difference in local recurrence between those patients having a radical mastectomy and those having had a simple mastectomy and post-operative radiotherapy.
In general, most of the patients with recurrent and/or metastatic disease have been treated by means of additive endocrine therapy rather than orchidectomy. In a previous report (Ribeiro, 1976 (Ribeiro, 1983) 
Discussion
The primary treatment of operable male breast carcinoma now mirrors the changes taking place in the management of female breast carcinoma, with simple mastectomy and radiotherapy replacing radical mastectomy. There would appear to be no detrimental effect on local recurrence or overall survival caused by this change.
In a previous report (Ribeiro, 1977) (1973) but not with other reports (Dao et al., 1973 , Calabresi et al., 1976 Nirmul et al., 1982) . The reasons for the difference may be in the methodology, the paucity of patients, the choice of controls, or even due to ethnic variations.
Finally, the management of male breast carcinoma should, as in the female counterpart, remain a continuously evolving process.
